Yuhan Corp. and Osang Healthcare said on Monday they have signed a global sales and distribution agreement for DangQLac, blood sugar suppressing probiotocs, at Yuhan's headquarters in Seoul, Thursday.
Under the agreement, Yuhan will grant overseas sales rights and supply of DangQLac to Osang Healthcare. Osang Healthcare will sell the product through its global distribution network with more than 140 partners in more than 100 countries.
Yuhan Corp. CEO Cho Wook-je (right) and Osang Healthcare Chairman Lee Dong-hyun pose for a photo after signing a global sales agreement in Seoul, on Thursday.
DangQLac is a probiotic health-functional food made from L. plantarum HAC01 strain.
The company claims it was the first probiotic product in Korea to receive recognition from the Ministry of Food and Drug Safety (MFDS) for its ability to reduce postprandial blood glucose. Human clinical trials confirmed a reduction in glycated hemoglobin and two-hour postprandial blood glucose levels, according to Yuhan. Since its launch in April 2023, sales have exceeded 12 billion won in six months, with cumulative sales reaching 50 billion won.
“Based on our mutual strategic partnership, we will drive the successful overseas expansion of DangQLac, a functional health food,” said Yuhan Corp. CEO Cho Wook-je. “We will continue to collaborate with Osang Healthcare in various areas, including health-functional foods.”
“This marks our first large-scale collaboration since signing a comprehensive business cooperation agreement with Yuhan in May 2023,” said Osang Healthcare Chairman Lee Dong-hyun. “Starting with DangQLac, we will explore new product opportunities to expand our global distribution business and establish it as a key revenue source, alongside our Covid-flu combo kit, which we recently began delivering to global companies.”